Russia completes clinical trials of second potential COVID-19 vaccine: RIA

MOSCOW (Reuters) - Russia has completed clinical trials of a second potential vaccine against COVID-19, developed by Siberia's Vector Institute, the RIA news agency cited Russian consumer safety watchdog Rospotrebnadzor as saying on Wednesday.

The institute completed early-stage human trials, known as Phase II, earlier this month.

(Reporting by Maria Kiselyova; Writing by Alexander Marrow; Editing by Gareth Jones)

09/30/2020 7:28

News, Photo and Web Search